CDTX Hits 52-Week High Amid Merck Acquisition Buzz
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 14 Nov 25
Source: Benzinga
Shares of Cidara Therapeutics Inc. (CDTX.O) soared to a 52-week high of $150.75, reflecting a remarkable 42.23% increase in after-hours trading. The surge follows news that Merck & Co. is nearing a deal to acquire the company, which specializes in long-acting antibody treatments for influenza. Investors are optimistic as the acquisition is expected to value Cidara at a premium above its current $3.3 billion market cap, with Merck competing against another pharmaceutical firm for the purchase. This acquisition could significantly enhance Merck's portfolio, particularly in flu protection, as Cidara's innovative therapies gain traction in the market.
Analyst Views on CDTX
Wall Street analysts forecast CDTX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CDTX is 209.67 USD with a low forecast of 173.00 USD and a high forecast of 221.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
2 Buy
6 Hold
0 Sell
Hold
Current: 221.380
Low
173.00
Averages
209.67
High
221.50
Current: 221.380
Low
173.00
Averages
209.67
High
221.50
About CDTX
Cidara Therapeutics, Inc. is a biotechnology company. The Company is using its Cloudbreak platform to develop drug-Fc conjugate (DFC), immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. The Company’s Cloudbreak platform enables development of DFCs that inhibit specific disease targets while simultaneously engaging the immune system. The Company’s lead DFC candidate CD388, is a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which has completed Phase I and Phase IIa clinical trials. Its oncology DFC candidate, CBO421, is a development candidate targeting CD73 for the treatment of solid tumors. Its Cloudbreak platform creates single molecule cocktails by coupling targeted small molecules and peptides to a human antibody fragment (Fc). The Company is also advancing multiple preclinical and discovery programs targeting cancer and autoimmune diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
